This is a Validated Antibody Database (VAD) review about mouse Pvr, based on 8 published articles (read how Labome selects the articles), using Pvr antibody in all methods. It is aimed to help Labome visitors find the most suited Pvr antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Pvr synonym: 3830421F03Rik; CD155; D7Ertd458e; HVED; PVS; Taa1; Tage4; mE4; necl-5

BioLegend
rat monoclonal (TX56)
  • flow cytometry; mouse; 1:50; fig 3d
BioLegend Pvr antibody (BioLegend, 131507) was used in flow cytometry on mouse samples at 1:50 (fig 3d). Proc Natl Acad Sci U S A (2022) ncbi
rat monoclonal (TX56)
  • flow cytometry; mouse; 1:200; loading ...; fig 2d, 3a
BioLegend Pvr antibody (Biolegend, 131512) was used in flow cytometry on mouse samples at 1:200 (fig 2d, 3a). Development (2022) ncbi
rat monoclonal (TX56)
  • immunohistochemistry; mouse; loading ...
BioLegend Pvr antibody (BioLegend, 131509) was used in immunohistochemistry on mouse samples . Nat Commun (2021) ncbi
rat monoclonal (TX56)
  • flow cytometry; mouse; 1:100
BioLegend Pvr antibody (BioLegend, TX56) was used in flow cytometry on mouse samples at 1:100. Nature (2020) ncbi
rat monoclonal (4.24.1)
  • flow cytometry; mouse; loading ...; fig s1b
BioLegend Pvr antibody (BioLegend, 4.24.1) was used in flow cytometry on mouse samples (fig s1b). J Clin Invest (2019) ncbi
Invitrogen
mouse monoclonal (D171)
  • ELISA; human; 0.2 ug/ml; loading ...; fig 1a
Invitrogen Pvr antibody (Thermo Fisher, D171) was used in ELISA on human samples at 0.2 ug/ml (fig 1a). Breast Cancer (2020) ncbi
mouse monoclonal (D171)
  • blocking or activating experiments; human; loading ...; fig 3a, 3b, 3c, 5a
Invitrogen Pvr antibody (NeoMarkers, D171) was used in blocking or activating experiments on human samples (fig 3a, 3b, 3c, 5a). Oncogene (2018) ncbi
rat monoclonal (TX56)
  • flow cytometry; mouse; fig 1
In order to study how DNAM-1 controls NK cell-mediated cytotoxicity and cytokine production, Invitrogen Pvr antibody (eBioscience, TX56) was used in flow cytometry on mouse samples (fig 1). J Exp Med (2015) ncbi
Articles Reviewed
  1. Ozmadenci D, Shankara Narayanan J, Andrew J, Ojalill M, Barrie A, Jiang S, et al. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. Proc Natl Acad Sci U S A. 2022;119:e2117065119 pubmed publisher
  2. Meléndez E, Chondronasiou D, Mosteiro L, Mart xed nez de Villarreal J, Fern xe1 ndez Alfara M, Lynch C, et al. Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development. 2022;149: pubmed publisher
  3. Van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, et al. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nat Commun. 2021;12:5906 pubmed publisher
  4. Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed publisher
  5. Iguchi Manaka A, Okumura G, Ichioka E, Kiyomatsu H, Ikeda T, Bando H, et al. High expression of soluble CD155 in estrogen receptor-negative breast cancer. Breast Cancer. 2020;27:92-99 pubmed publisher
  6. Vuckovic S, Minnie S, Smith D, Gartlan K, Watkins T, Markey K, et al. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. J Clin Invest. 2019;129:106-121 pubmed publisher
  7. Stamm H, Klingler F, Grossjohann E, Muschhammer J, Vettorazzi E, Heuser M, et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37:5269-5280 pubmed publisher
  8. Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A. DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med. 2015;212:2165-82 pubmed publisher